• Accelero_Autumn_2017_1.jpg
  • Accelero_Autumn_2017_2.jpg
  • Accelero_Autumn_2017_3.jpg
  • Accelero_Autumn_2017_3a.jpg
  • Accelero_Autumn_2017_4.jpg
  • Accelero_Autumn_2017_5.jpg
  • Accelero_Autumn_2017_5a.jpg
  • Accelero_Autumn_2017_7.jpg
  • Accelero_Autumn_2017_8.jpg
  • Accelero_Autumn_2017_9.jpg

Accelero® Bioanalytics is aspired to become a preferred provider of a comprehensive drug development portfolio for the nucleic acid biotechnology. Within this bioanalytics section we are proud to present some scientific background knowledge which we think could be useful for our customers. Just klick one of the links below:

(1) Basic scientific knowledge on microRNA (miRNA) therapeutics.

(2) Good Laboratory Practice (GLP) compliant Real-Time RT-qPCR is obligatory for the microRNA (miRNA), siRNA, and aptamer drug development community.

(3) The huge portfolio of ligand binding assays can also be performed under Good Laboratory Practice (GLP) regulations.

(4) The quantification of innovative peptide or protein therapeutics in real-time is one of the major advancements in immunoassay sensitivity.